Related Experiment Video

Updated: Jun 16, 2026

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

990

Neoadjuvant Aumolertinib for unresectable stage III EGFR-mutant non-small cell lung cancer: a single-arm phase II

Dongliang Bian1, Shuyu Ji1, Yue Liu1

  • 1Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, 200433, China.

Nature Communications
|April 1, 2025
PubMed

Insights

Neoadjuvant Aumolertinib demonstrated significant efficacy in advanced EGFR-mutant non-small cell lung cancer, achieving a high objective response rate and enabling surgical conversion in unresectable stage III patients.

Area of Science:

  • Oncology
  • Medical Research
  • Pharmacology

Background:

  • Advanced EGFR-mutant non-small cell lung cancer (NSCLCm) presents treatment challenges.
  • Third-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs) like Aumolertinib are key therapies.
  • Neoadjuvant treatment strategies are evolving for unresectable NSCLCm.

Purpose of the Study:

  • To assess the feasibility and efficacy of neoadjuvant Aumolertinib in unresectable stage III NSCLCm.
  • To evaluate objective response rate (ORR) as the primary endpoint.
  • To determine secondary endpoints including pathological response, resection rates, survival, and safety.

Main Methods:

  • A single-arm, phase II clinical trial (NCT04685070) enrolled 56 patients.
  • 51 patients received neoadjuvant Aumolertinib (110 mg/day orally).
  • Endpoints included ORR, major pathological response (MPR), pathological complete response (pCR), R0 resection, event-free survival (EFS), overall survival (OS), and treatment-related adverse events (TRAEs).

Main Results:

  • ORR was 70.6%, meeting the primary endpoint.
  • 45.1% of patients converted to resectable disease, with 100% R0 resection rate among those operated on.
  • MPR and pCR rates were 21.7% and 13.0%, respectively. Median EFS and OS were not reached; 1- and 2-year EFS rates were 88.2% and 58.8%.

Conclusions:

  • Neoadjuvant Aumolertinib shows promising efficacy and a notable surgical conversion rate for unresectable stage III NSCLCm.
  • The treatment demonstrated a tolerable safety profile.
  • RNA-sequencing suggested Aumolertinib may remodel the tumor microenvironment by increasing CD8+ T-cell infiltration.

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

7.9K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.7K

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...